Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status

JAMA. 2022 Apr 5;327(13):1234-1235. doi: 10.1001/jama.2022.2361.
No abstract available

Publication types

  • Comment

MeSH terms

  • COVID-19* / complications
  • Fibrinolytic Agents* / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Inflammation / etiology
  • Thromboinflammation* / drug therapy
  • Thromboinflammation* / etiology
  • Thrombosis / etiology
  • Thrombosis / prevention & control
  • Thrombosis / therapy

Substances

  • Fibrinolytic Agents